Sean McClain, AbSci

On a mis­sion to 'u­ni­fy' drug dis­cov­ery and cell-line de­vel­op­ment, Ab­Sci ac­quires AI out­fit De­n­ovi­um

Imag­ine dis­cov­er­ing a drug and cell line at the click of a but­ton. That’s the goal of Ab­Sci CEO Sean Mc­Clain — and on Mon­day, he closed on a deal to buy De­n­ovi­um and its AI en­gine that tran­scends the hu­man brain and even the best of lab tools.

“Es­sen­tial­ly what we’re do­ing is we’re tak­ing all this da­ta…that looks at man­u­fac­tura­bil­i­ty and drug func­tion­al­i­ty, and then feed­ing it in­to the AI plat­form that’s con­tin­u­al­ly learn­ing,” Mc­Clain told End­points. “Every mol­e­cule we have is fed in­to the mod­el,” he said.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.